Logo for OriCiro

Meet an Unreasonable Venture


Creating a better bioeconomy with innovative genome technologies.

Photo of Seiji Hirasaki

Seiji Hirasaki

CEO at OriCiro

More about Seiji »
Employees 21–50
Headquarters Tokyo, Japan
OriCiro is a pioneer of cell-free genome technology, providing a powerful tool for research and development aimed at unlocking the possibility of synthetic biology. The company’s proprietary technology focuses on the development and commercialization of cell-free synthesis and amplification technologies of large DNA molecules aiming to replace conventional cell-based methodology by not only streamlining current research processes, but also widening the scope of genomics research significantly. The company also owns a suite of genome technologies, including the assembly of DNA fragments and genome editing. Synthetic biology, through which new medicines and useful proteins can be produced more efficiently by modified and/or synthesized genomes — is developing rapidly worldwide. OriCiro’s technologies have potential markets in a variety of industries including the pharmaceutical, diagnostic, industrial biotech, food, and agricultural sectors.

Currently Operating in Eight Regions

Work at OriCiro

More Ventures in Health

Get the Unreasonable Newsletter

Get twice-monthly updates on OriCiro and over 314 other ventures working to solve the world's toughest problems.

Read our Privacy Policy.